Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.

@article{Rosen1996SuraminIH,
  title={Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.},
  author={Peter. J. Rosen and Erika Mendoza and Elliot M. Landaw and Bartly J Mondino and Michael C. Graves and James H. McBride and P Turcillo and Jean B. Dekernion and Arie S. Belldegrun},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1996},
  volume={14 5},
  pages={1626-36}
}
PURPOSE To confirm the previously reported high response rates and prolonged survival in hormone-refractory prostate cancer treated with suramin. PATIENTS AND METHODS Thirty-six eligible patients with hormone-refractory prostate cancer with either measurable disease or bone disease only and a prostate-specific antigen (PSA) level greater than 50 ng/mL were enrolled. Treatment consisted of two 8-week courses of outpatient-based therapy with an interposed rest period. A bayesian adaptive… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…